# Elevance Health (ELV) Q2 2026 earnings

Results filed 2026-07-15 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/elv/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1156039/000115603926000058/0001156039-26-000058-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Elevance Health is accelerating targeted investments in cost management, member experience, provider connectivity and Carelon's value-based care while Medicaid cost pressure persists, aiming to return to at least 12% adjusted EPS growth in 2027.

Elevance repositioned its portfolio this quarter: Medicare Advantage and Employer Group risk membership shrank on purpose, and Medicaid membership fell as expected, while Individual ACA and Medicare Advantage performed better than planned. Total medical membership was about 44.9 million, down 469 thousand from the prior quarter, partly from a known commercial fee-based customer transition. Carelon kept scaling risk-based services and specialty pharmacy, though CarelonRx script volumes fell with health plan attrition.
Management plans to use a non-recurring below-the-line benefit to fund one-time investments in medical cost management, member experience, provider connectivity, operating efficiency and Carelon's value-based capabilities. It targets at least 12% adjusted EPS growth in 2027 off a $26.00 baseline. The tension is that Medicaid cost trend remains elevated, with 2026 described as a trough for Medicaid margins, and the plan depends on new investments paying off.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Operating revenue | $49.8 billion | up 0.8% from 2Q 2025 |  |
| Shareholders' net income | $1,463 | down 16.1% from a year ago | GAAP |
| Diluted EPS | $6.71 | down 13.1% from a year ago | GAAP |
| Adjusted diluted EPS | $7.45 | down 15.7% from a year ago | non-GAAP |
| Operating gain | $1,763 | down 27.3% from a year ago | GAAP |
| Operating margin | 3.5% | down 140 bp from a year ago | GAAP |
| Operating cash flow | $1.9 billion |  | GAAP |
| Benefit expense ratio | 89.7% | up 80 basis points year over year |  |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Health Benefits operating revenue | $42,720 | up 2.7% |
| CarelonRx operating revenue | $11,250 | up 5.7% |
| Carelon Services operating revenue | $7,975 | up 7.2% |
| Total medical membership (thousands) | 44,949 | down 1.5% from a year ago |
| Medicare Advantage membership (thousands) | 1,897 | down 15.9% from a year ago |
| Individual ACA operating revenue | $2,720 | up 16.8% |
| CarelonRx quarterly adjusted scripts (millions) | 80.9 | down 2.9% from a year ago |
| Carelon Services consumers served (millions) | 92.4 | down 5.0% from a year ago |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Adjusted diluted EPS | full year 2026 | at least $27.00 |
| Diluted EPS (GAAP) | full year 2026 | at least $20.10 |
| Operating cash flow | full year 2026 | at least $6.0 billion |
| Adjusted diluted EPS growth | 2027 | at least 12% |

## Key takeaways

1. **Portfolio repositioning is shrinking Medicare Advantage and group risk** Medicare Advantage membership fell 15.9% year over year to 1,897 thousand, and Employer Group risk-based membership fell 5.5%. Management calls these intentional actions, trading volume for margin.
2. **Investments target cost detection, members, providers and Carelon** Elevance is funding one-time work to detect cost trends earlier, guide members with personalized support, reduce provider friction such as avoidable denials, and expand Carelon. These are meant to make performance more consistent.
3. **Medicaid is the main pressure point** Elevated Medicaid cost trend drove the higher benefit expense ratio, and Medicaid membership fell to 8,358 thousand. Management says Medicaid supports its unchanged margin guidance and views 2026 as a trough for Medicaid margins.
4. **Carelon is scaling risk-based services and CareBridge** Carelon Services revenue grew on risk-based solutions, and plans include expanding CareBridge to new markets and growing external client relationships. Margins are held back by ongoing investment in the platform.
5. **Individual ACA and Medicare Advantage beat expectations** Better-than-expected Medicare Advantage and Individual ACA performance led the benefit expense ratio. Individual ACA membership fell 7.5% sequentially to 1,317 thousand, but Individual revenue still grew 16.8% on pricing.

## Questions

**What is Elevance investing in with its raised guidance?** A non-recurring below-the-line benefit funds one-time investments in medical cost management, member experience, provider connectivity, operating efficiency and Carelon's value-based capabilities. The aim is earlier detection of cost trends and less friction for members and providers.
**How is Elevance's membership changing?** Medical membership was about 44.9 million, down 469 thousand from March. The causes were a known commercial fee-based customer transition and expected attrition in Individual ACA and Medicaid, plus deliberate repositioning in Medicare Advantage and Employer Group risk.
**What is happening in Medicaid?** Medicaid cost trend remains elevated and Medicaid membership declined 4.3% year over year. Management says it is managing within its full-year margin framework, with rate alignment and targeted cost-of-care actions, and views 2026 as a trough for Medicaid margins.
**How is Carelon performing?** Carelon operating revenue grew 6% as risk-based Carelon Services scaled and CarelonRx revenue per script rose. CarelonRx adjusted scripts fell 2.9% on health plan attrition, and specialty pharmacy profitability improved.
**What is management's outlook beyond 2026?** Management expects to return to at least 12% adjusted EPS growth in 2027 off a 2026 baseline of $26.00. The long-term plan targets high single digit revenue growth and adjusted operating margin expanding to 5.0%-6.0%.

## Slides and investor documents

- [Q2 2026 Supplemental Earnings Presentation](https://s202.q4cdn.com/665319960/files/doc_financials/2026/q2/2Q2026ELVSupplementalEarningsPresentation.pdf) (Slide deck)
- [Q2 2026 Earnings Transcript](https://s202.q4cdn.com/665319960/files/doc_financials/2026/q2/ELV-USQ_Transcript_2026-07-15.pdf) (Company's official transcript)
- [Q2 2026 Earnings Webcast](https://events.q4inc.com/attendee/666180842) (Webcast replay)
- [Q2 2026 Form 10-Q](https://s202.q4cdn.com/665319960/files/doc_financials/2026/q2/2Q2026ELV10Q.pdf) (Document)

